Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.
Site search
2026
June 25, 2026
Taiho Pharmaceutical Earns First Silver Medal in EcoVadis Sustainability Rating
May 14, 2026
U.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy
April 28, 2026
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
April 28, 2026
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development
April 21, 2026
Update on the Phase 3 STAR-121 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab in Non-Small Cell Lung Cancer
March 10, 2026
Taiho Pharmaceutical Announces Personnel Changes
January 14, 2026
Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group
January 05, 2026
Sanofi and Taiho Announce Sales Transfer of Anticancer Agent JEVTANA® Intravenous Infusion 60 mg
News Releases
Select year from the Back Number
Back Number
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
